GENUS PLC

GNS
Delayed Quote. Delayed  - 01/21 11:36:12 am
3804GBX -5.51%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Other Biotechnology & Medical Research
Genus PLC is a United Kingdom-based animal genetics company. The Company provides farmers with genetics that enable them to produce animal protein for breeding pigs and cattle, in the form of meat and milk. The Company’s operating segments includes Genus PIC, Genus ABS and Research and Development. The Genus PIC segment is engaged in porcine sales busines, excluding Asia, and serves porcine customers in North America, Latin America, and Europe. The Genus ABS segment is engaged in bovine sales business, excluding Asia, and serves dairy and beef customers in North America, Latin America, and Europe. The Research and Development globally spend on development activities. The Company operates approximately around 25 countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

Number of employees : 3 265 people.
Sales per Business
2021
Genus PIC315.6055%
Genus ABS250.1043.5%
Porcine Product Development7.301.3%
Bovine Product Development1.300.2%
Research and Development--
GBP in Million
Sales per region
20202021
North America226.4041.1%214.7037.4%
Asia70.8012.8%101.5017.7%
United Kingdom94.4017.1%92.2016.1%
Latin America81.8014.8%83.8014.6%
Rest of Europe, Middle East, Russia and Africa78.0014.1%82.1014.3%
GBP in Million
Managers
Name Title
Stephen Wilson Chief Executive Officer & Executive Director
Alison Henriksen Chief Financial Officer & Director
Iain George Thomas Ferguson Non-Executive Chairman
Elena Rice Chief Scientific Officer
Bill Christianson Chief Operating Officer
Lykele J. van der Broek Independent Non-Executive Director
Lysanne Mary Gray Independent Non-Executive Director
Lesley Mary Samuel Knox Senior Independent Non-Executive Director
Jason Chin Non-Executive Director
Dan Hartley Secretary & Group General Counsel
Shareholders
Name Equities %
Baillie Gifford & Co. 5,416,054 8.24%
Threadneedle Asset Management Ltd. 3,582,072 5.45%
Aberdeen Asset Managers Ltd. 2,484,710 3.78%
The Vanguard Group, Inc. 2,216,834 3.37%
Capital Research & Management Co. (Global Investors) 1,958,771 2.98%
Norges Bank Investment Management 1,886,699 2.87%
BlackRock Fund Advisors 1,748,359 2.66%
Capital Research & Management Co. (World Investors) 1,519,000 2.31%
Devon Equity Management Ltd. 1,515,000 2.30%
Royal London Asset Management Ltd. 1,485,000 2.26%
Sector Other Biotechnology & Medical Research
1st jan.Capi. (M$)
GENUS PLC-23.01%3 360
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508
CELLTRION, INC.-17.42%19 126
PPD, INC.38.16%16 614
INCYTE CORPORATION1.89%16 520
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.-11.86%16 384
ALNYLAM PHARMACEUTICALS, INC.-19.56%16 315
HANGZHOU TIGERMED CONSULTING CO., LTD-8.92%15 060
PHARMARON BEIJING CO., LTD.-12.03%14 881
BIO-TECHNE CORPORATION-29.04%14 425
QIAGEN N.V.-10.81%11 054
PRA HEALTH SCIENCES, INC.0.00%10 965
UNITED THERAPEUTICS CORPORATION-7.41%9 010
SYNEOS HEALTH, INC.-16.01%8 942
BACHEM HOLDING AG-24.30%8 761
GENSCRIPT BIOTECH CORPORATION-9.42%8 435
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.-20.12%7 210
Brand Portfolio
ABS
ABS
» More brands of Genus Plc